The PR doesn’t actually say that, but it may as well have. TYME has $92M of cash (as of 12/31/21) and nothing of consequence in the clinic following the failure of SM-88 in pancreatic cancer two months ago (#msg-167645887).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”